Your browser doesn't support javascript.
loading
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
Karnes, Jason H; Rettie, Allan E; Somogyi, Andrew A; Huddart, Rachel; Fohner, Alison E; Formea, Christine M; Ta Michael Lee, Ming; Llerena, Adrian; Whirl-Carrillo, Michelle; Klein, Teri E; Phillips, Elizabeth J; Mintzer, Scott; Gaedigk, Andrea; Caudle, Kelly E; Callaghan, John T.
Afiliação
  • Karnes JH; Department of Pharmacy Practice & Science, University of Arizona College of Pharmacy, Tucson, Arizona, USA.
  • Rettie AE; Sarver Heart Center, University of Arizona College of Medicine, Tucson, Arizona, USA.
  • Somogyi AA; Department of Medicinal Chemistry, University of Washington School of Pharmacy, Seattle, Washington, USA.
  • Huddart R; Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Fohner AE; Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Formea CM; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Ta Michael Lee M; Institute of Public Health Genetics, University of Washington, Seattle, Washington, USA.
  • Llerena A; Department of Pharmacy and Intermountain Precision Genomics, Intermountain Healthcare, Salt Lake City, Utah, USA.
  • Whirl-Carrillo M; Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.
  • Klein TE; INUBE Extremadura University Biosanitary Research Institute and Medical School, Badajoz, Spain.
  • Phillips EJ; Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Mintzer S; Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Gaedigk A; Department of Medicine, Stanford University, Stanford, California, USA.
  • Caudle KE; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Callaghan JT; Department of Neurology, Thomas Jefferson University Hospital Methodist Hospital Division of Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Clin Pharmacol Ther ; 109(2): 302-309, 2021 02.
Article em En | MEDLINE | ID: mdl-32779747
ABSTRACT
Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*1502 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenitoína / Antígenos HLA-B / Citocromo P-450 CYP2C9 Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenitoína / Antígenos HLA-B / Citocromo P-450 CYP2C9 Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article